King & Spalding LLP‘s emerging companies and venture capital team sits within its corporate department and is well known for advising early-stage life sciences, healthcare, and technology companies. Beyond assisting with financings, the team is recognised for its track record in exit transactions, including both M&A and IPO. Laura Bushnell, Daniel Kahan, and Tom Knox jointly steer the practice. From Silicon Valley, Bushnell has a strong reputation for her expertise in emerging growth companies, Miami-based Kahan is an expert on fintech startups, and Northern Virginia-based Knox handles investments on both the venture-backed company and investor sides.
Legal 500 Editorial commentary
Key clients
- ## INSERTED START: 11-12-2025 09:35:33
- HeartFlow
- Eos Venture Partners
- Virtru
- ThreatMate
- Capital One
- Pieces Technologies
- ThreatQuotient
- SmartSuite Holdings
- Shirley OS
- Studylog Systems
- Virtru Corporation
Work highlights
Advised Heartflow in its $98 million convertible notes financing and as life sciences regulatory counsel and special counsel for certain corporate matters in its $316.7 million Nasdaq initial public offering.
Represented Virtru in its $50 million Series D financing, led by ICONIQ Capital, with participation from existing investors Bessemer Venture Partners, Foundry Capital, and Chertoff Group.
Represented EOS Venture Partners in Players Health's $60 million Series C financing led by Bluestone Equity Partners.
Practice head
Laura I. Bushnell; Daniel Kahan; Tom Knox
Other key lawyers
Eric Nyman